JPRN-UMIN000006819已完成2 期
Multicenter Phase II Study of FOLFIRI and biweekly Cetuximab combination chemotherapy as First Line Therapy in Patients with Wild Type KRAS Metastatic Colorectal Cancer. ( FIRBIC ) - Phase II Study of FOLFIRI and biweekly Cetuximab with Wild Type KRAS mCRC. (FIRBIC)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1)Severe bone marrow suppression (2)History of severe allergy (3) Active infection (include type B , C a hepatitis carrier) (4)Wattery diarrhea (5)Paralytic or mechanical bowel obstruction (6)Massive pleural effusion or ascites (7)Severe heart failure (8) Uncontrolled DM (9)Comorbidity or history of interstitial lung disease or pulmonary fibrosis (10)Jaundice (11) Multiple bone metastasis (12)Simultaneous or metachronous double cancers (Carcinoma in situ is eligible). (13)Patients who is receiving Atazanavir Sulfate (14) Mental disorder, central nervous system disorder or severe cerebrovasculara disease (15) Radiotherapy to target lesion (Adjuvant radiation therapy before and after the curative resection ) (16) Pregnant or lactating women or women of childbearing potential or men who are planning family (17)Severe complications (18)Symptomatic brain metastasis (19) Active bleeding or blood transfusion within two weeks. (20) Not appropriate for the study at the physician's assessment
研究者
相似试验
已完成
2 期
Multicenter phase II study of FOLFIRI and bevacizumab as second-line treatment in advanced or recurrent colorectal cancer.Colorectal CancerJPRN-UMIN000001817Yakult Honsha Co.,Ltd.90
进行中（未招募）
1 期
Evaluation of the efficacy of a combinaison treatment based upon immunotherapy + chemotherapy to treat patient with a stomach cancerAdvanced gastric or gastro-oesophageal junction adenocarcinomaMedDRA version: 20.0 Level: LLT Classification code 10042080 Term: Stomach cancer System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10026476 Term: Malignant neoplasm of stomach System Organ Class: 100000004864EUCTR2018-002014-13-FRFédération Francophone de Cancérologie Digestive94
进行中（未招募）
1 期
Everest 2. A study for previously not treated patients with spread colorectal cancer characterized by the presence of wild non mutated K-Ras gene involving standard chemotherapy (FOLFIRI) and cetuximab either at standard or increased doses depending on the skin reactions determined by treatment.K-Ras wild type metastatic colorectal cancerMedDRA version: 16.0Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-009992-36-ATniversity Hospital Leuven130
进行中（未招募）
1 期
A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment of K-Ras wild type metastatic colorectal cancer: Everest 2 - Everest 2K-Ras wild type metastatic colorectal cancerMedDRA version: 12.1Level: LLTClassification code 10052358Term: Colorectal cancer metastaticEUCTR2009-009992-36-BEniversity Hospital Leuven375
进行中（未招募）
1 期
Everest 2. A study for previously not treated patients with spread colorectal cancer characterized by the presence of wild non mutated K-Ras gene involving standard chemotherapy (FOLFIRI) and cetuximab either at standard or increased doses depending on the skin reactions determined by treatment.K-Ras wild type metastatic colorectal cancerMedDRA version: 13.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-009992-36-HUniversity Hospital Leuven108